Recent developments in the treatment of familial hypercholesterolemia: A review of several new drug classes

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 6, 2013, Pages 696-705

  Wilkinson, Michael J ^a   Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein B synthesis inhibitior; Cholesterol ester transfer protein (CETP) inhibitor; Familial hypercholesterolemia; Hyperlipidemia; Lipidology; Low density lipoprotein cholesterol (LDL C); Microsomal trigylceride transfer protein (MTP) inhibitor; Prevention; Pro protein convertase subtilisin kexin 9 (PCSK9) inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; ALIROCUMAB; ANACETRAPIB; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BICARBONATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; PLACEBO; POTASSIUM; PROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; TORCETRAPIB; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYMPTOM; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GENETIC DISORDER; HEPATOMEGALY; HUMAN; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LIVER TOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 84890562042     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0272-3     Document Type: Review

References (18)

1. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipid. 2011;5:133-40.
2. National Institute for Health and Care Excellence (NICE). 2008. Familial Hypercholesterolaemia (CG71). (Accessed September 11, 2013, at http://www.nice.org.uk/cg71.)
3. Reiner Z et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
4. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013;24:246-50.
5. Cuchel M, Bloedon LT, Szapary PO, Kolansy DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-56.
6. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-6. This study showed that lomitapide, a microsomal triglyceride transfer protein inhibitor, produces significant reductions in LDL cholesterol in patients with homozygous familial hypercholesterolemia, and found that elevations in transaminase levels could be corrected with dose reduction or temporary cessation of the medication. These findings help to establish a role for the use of lomitapide in clinical practice, and provide guidance for addressing the potential side effect of transaminase elevation.
7. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34:962-71.
8. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous famililal hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006. This study demonstrated that mipomersen, an apolipoprotein B synthesis inhibitor, has beneficial effects on the lipid profile of patients with homozygous familial hypercholesterolemia, including a reduction in LDL cholesterol, and that it is generally safe to use.
9. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413-9.
10. Barter PJ, Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J. P.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K. A.; Fisher, M. R.; Tall, A. R.; and B. Brewer Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med 2007;357.
11. Kastelein JJP, van Leuven S. I.; Burgess, L.; Evans, G. W.; Kuivenhoven, J. A.; Barter, P. J.; Revkin, J. H.; Grobbee, D. E.; Riley, W. A.; Shear, C. L.; Duggan, W. T.; and M. L. Bots. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med 2007;356.
12. Cannon CP, Shah, S.; Dansky, H. M.; Davidson, M.; Brinton, E. A.; Gotto, A. M.; Stepanavage, M.; Xueyu Liu, S.; Gibbons, P.; Ashraf, T. B.; Zafarino, J.; Mitchel, Y.; Barter, P. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N Engl J Med 2010;363.
13. Davidson MH. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. Journal of Clinical Lipidology. 2013;7:S11-5.
14. Cohen JC, Boerwinkle, E.; Mosley, T. H.; and H. H. Hobbs. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354.
15. Stein EA, Mellis, S.; Yancopoulos, G. D.; Stahl, N.; Logan, D.; Smith, W. B.; Lisbon, E.; Gutierrez, M.; Webb, C.; Wu, R.; Du, Y.; Kranz, T.; Gasparino, E.; and G. D. Swergold. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366.
16. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-53. This study showed that SAR236553, a monoclonal antibody against PCSK9, was generally well-tolerated and reduced LDL cholesterol in a dose and frequency dependent manner in patients on atorvastatin, but with baseline LDL cholesterol levels still ≥ 100 mg/dl. Although this was not a study of the treatment of familial hypercholesterolemia, the significance of these findings suggests that antibodies against PCSK9 should be tested further and considered among the potential emerging therapies for familial hypercholesterolemia.
17. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.
18. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-17.